First mRNA flu shot approved by FDA bodes well for improving drugs of the future
The US Food and Drug Administration approved the first messenger RNA (mRNA)-based seasonal influenza vaccine on August 5, 2026
The vaccine received standard approval for adults aged 50–64 and accelerated approval for adults 65 and older
Clinical trial data covering over 40,000 adults aged 50 and above found the vaccine to be more effective than standard flu shots during the 2024–25 respiratory virus season
The approval followed an earlier regulatory setback in which the agency initially declined to review the vaccine before reversing course
The development is being viewed as a proof of concept for using mRNA platforms to develop faster, more adaptable vaccines and therapeutics beyond COVID-19
mRNA Vaccine Technology — Mechanism and Platform Advantage
mRNA vaccines work by delivering a synthetic messenger RNA sequence, encoding a target pathogen protein, into human cells using a protective delivery vehicle. The cell's own ribosomal machinery then translates this mRNA into the target protein, which triggers an adaptive immune response without introducing any live or attenuated pathogen.
Key Details
- The mRNA is encapsulated in lipid nanoparticles (LNPs), synthetic spherical carriers roughly 100 nanometers in diameter, which protect the fragile RNA from degradation and enable its entry into cells
- Unlike traditional inactivated or live-attenuated flu vaccines — grown in chicken eggs or cell culture over months — mRNA vaccine sequences can be redesigned rapidly once a pathogen's genetic sequence is known, since only the encoded protein sequence changes between different vaccine targets
- This platform flexibility was first proven at scale during the COVID-19 pandemic, with mRNA vaccines from global developers authorised in 2020–21
- Because the underlying LNP-delivery chemistry is reusable across targets, mRNA technology is described as "programmable" — reducing development timelines and de-risking manufacturing for new disease targets
The flu vaccine approval demonstrates that the mRNA platform first validated for COVID-19 can be extended to endemic seasonal diseases, reinforcing its potential as a general-purpose vaccine (and, longer-term, therapeutic) delivery technology.
India's mRNA Vaccine Capability — GEMCOVAC-19
India developed its own indigenous mRNA vaccine during the COVID-19 pandemic, positioning the country among a small group of nations with demonstrated mRNA vaccine manufacturing capability.
Key Details
- GEMCOVAC-19, developed by Gennova Biopharmaceuticals (Pune), received Emergency Use Authorisation from the Drugs Controller General of India (DCGI) in June 2022 — India's first indigenously developed mRNA vaccine and the third mRNA COVID-19 vaccine authorised anywhere in the world
- A key differentiator was thermostability: GEMCOVAC-19 used a freeze-dried (lyophilised) formulation allowing storage at 2–8°C, unlike other mRNA COVID-19 vaccines of that era which required ultra-cold-chain storage
- It is a two-dose intramuscular vaccine administered 28 days apart
- The vaccine's development was supported under India's COVID-19 vaccine mission architecture involving the Department of Biotechnology and Biotechnology Industry Research Assistance Council (BIRAC)
As global regulators extend mRNA approvals beyond COVID-19 into seasonal influenza, India's existing indigenous mRNA platform (demonstrated via GEMCOVAC-19) provides a domestic technology base that could similarly be redirected toward other disease targets.
Beyond Vaccines — mRNA and Gene-Editing Therapeutics
Researchers are extending mRNA delivery technology beyond vaccines into gene-editing and protein-replacement therapeutics, using the same lipid nanoparticle delivery principle to carry therapeutic payloads such as CRISPR-Cas9 components into cells.
Key Details
- CRISPR-Cas9 is a gene-editing tool that uses a guide RNA to direct the Cas9 enzyme to a specific DNA sequence, where it creates a precise cut enabling gene disruption, correction, or insertion
- mRNA-LNP delivery of CRISPR components (rather than viral vectors) allows transient expression of the editing machinery, reducing off-target and immune-related risks associated with permanent viral-vector-based gene therapy
- Two technical hurdles noted for broader mRNA therapeutic use are the short intracellular half-life of mRNA molecules and unwanted innate immune activation triggered by manufacturing impurities in the RNA product
- Applications under active research include mRNA-based cancer vaccines (encoding tumour-specific neoantigens) and protein-replacement therapies for rare genetic disorders
The regulatory validation of a second major mRNA-based product (after COVID-19 vaccines) strengthens the platform's credibility for extending into these more complex gene-editing and therapeutic applications, an area of active biotechnology research relevant to India's own biotech and pharma sector.
- FDA approval date: August 5, 2026
- Approved age groups: standard approval for ages 50–64; accelerated approval for ages 65 and above
- Trial size: over 40,000 adults aged 50+ enrolled in the efficacy study
- Efficacy claim: approximately 27% more effective than standard flu vaccines during the 2024–25 season
- India's first mRNA vaccine (GEMCOVAC-19): DCGI Emergency Use Authorisation, June 2022, developed by Gennova Biopharmaceuticals
- Lipid nanoparticles used in mRNA delivery are approximately 100 nanometers in diameter